Literature DB >> 15521019

Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation.

Angela Dolganiuc1, Shilpa Oak, Karen Kodys, Douglas T Golenbock, Robert W Finberg, Evelyn Kurt-Jones, Gyongyi Szabo.   

Abstract

BACKGROUND AND AIMS: Recent evidence suggests that toll-like receptors (TLRs) recognize certain viruses. We reported that hepatitis C virus (HCV) core and nonstructural 3 (NS3) proteins activate inflammatory pathways in monocytes. The aim of this study was to investigate the role of TLRs in innate immune cell activation by core and NS3 proteins.
METHODS: Human monocytes, human embryonic kidney cells transfected with TLR2, and peritoneal macrophages from TLR2, MyD88 knockout, and wild-type mice were studied to determine intracellular signaling and proinflammatory cytokine induction by HCV proteins.
RESULTS: HCV core and NS3 proteins triggered inflammatory cell activation via the pattern recognition receptor TLR2 and failed to activate macrophages from TLR2 or MyD88-deficient mice. HCV core and NS3 induced interleukin (IL)-1 receptor-associated kinase (IRAK) activity, phosphorylation of p38, extracellular regulated (ERK), and c-jun N-terminal (JNK) kinases and induced AP-1 activation. Activation of nuclear factor-kappaB by core and NS3 was associated with increased IkappaBalpha phosphorylation. TLR2-mediated cell activation was dependent on the conformation of core and NS3 proteins and required sequences in the regions of aa 2-122 in core and aa 1450-1643 in NS3. Although cellular uptake of core and NS3 proteins was independent of TLR2 expression, cell activation required TLR2. HCV core protein and TLR2 showed intracellular colocalization. The hyper-elevated TNF-alpha induction by TLR2 ligands in monocytes of HCV-infected patients was not due to increased TLR2 expression.
CONCLUSIONS: HCV core and NS3 proteins trigger inflammatory pathways via TLR2 that may affect viral recognition and contribute to activation of the innate immune system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15521019     DOI: 10.1053/j.gastro.2004.08.067

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  121 in total

Review 1.  Role of lipid rafts in liver health and disease.

Authors:  Angela Dolganiuc
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells.

Authors:  Jan Petrasek; Angela Dolganiuc; Timea Csak; Bharath Nath; Istvan Hritz; Karen Kodys; Donna Catalano; Evelyn Kurt-Jones; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Hepatology       Date:  2011-01-10       Impact factor: 17.425

Review 3.  Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion.

Authors:  Søren Jensen; Allan Randrup Thomsen
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

4.  Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner.

Authors:  Wenyu Lin; Wei-Lun Tsai; Run-Xuan Shao; Guoyang Wu; Lee F Peng; Lydia L Barlow; Woo Jin Chung; Leiliang Zhang; Hong Zhao; Jae-Young Jang; Raymond T Chung
Journal:  Gastroenterology       Date:  2010-03-12       Impact factor: 22.682

Review 5.  Recent insights into the role of Toll-like receptors in viral infection.

Authors:  M Carty; A G Bowie
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

6.  PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection.

Authors:  Cheng J Ma; Lei Ni; Ying Zhang; C L Zhang; Xiao Y Wu; Antwan N Atia; Penny Thayer; Jonathan P Moorman; Zhi Q Yao
Journal:  Immunology       Date:  2010-11-23       Impact factor: 7.397

7.  Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.

Authors:  Dennis J Hartigan-O'Connor; Din Lin; James C Ryan; Valentina A Shvachko; Myrna L Cozen; Mark R Segal; Norah A Terrault; Lewis L Lanier; M Michele Manos; Joseph M McCune
Journal:  J Infect Dis       Date:  2013-12-10       Impact factor: 5.226

Review 8.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 9.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

10.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.